8月7日，阿尔尼拉姆制药公司盘中下跌5.04%，报217.2美元/股，成交额2.71亿美元。
消息面上，公司此前于7月30日发布Q2财报，虽调整后EPS 1.84美元超预期18.71%、同比增长475%，但营收12.91亿美元不及预期的13.23亿美元，同时将全年净产品收入指引从49亿-53亿美元下调至47亿-51亿美元。公司表示Amvuttra在ATTR-CM适应症的二线治疗需求正在正常化，早期积压需求释放阶段已过。财报公布后股价单日暴跌约28%，此后虽有技术性反弹，但市场对增长斜率放缓的担忧仍在消化中。RBC将目标价从445美元大幅下调至350美元，Stifel下调至318美元，均维持正面评级但承认短期不确定性上升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.